Bronchiectasis is a complicating factor in more than 30 diseases, including asthma, COVID-19, chronic obstructive pulmonary disease (COPD), nontuberculous mycobacterial infections (NTM) and autoimmune diseases. It is a condition that dilates and scars the airways, making breathing increasingly difficult. The American Lung Association estimates that up to half a million people in the United States have been diagnosed with bronchiectasis — yet it often goes undiagnosed, and many more are likely to have it. Join expert pulmonologist Dr. Lommatzsch to hear how National Jewish Health has been treating bronchiectasis patients for decades, often with effective, non-pharmaceutical options. More recently, our scientists have been conducting research on a promising bronchiectasis drug that is currently in phase 3 clinical trials.
